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Abstract
Many pathogenic enveloped viruses, including HIV-1, escape complement-mediated virolysis by 
incorporating host cell regulators of complement activation into their own viral envelope. The 
presence of complement regulators including CD59 on the external surface of the viral envelope 
confers resistance to complement-mediated virolysis, which may explain why human pathogenic 
viruses such as HIV-1 are not neutralized by complement in human fluids, even in the presence of 
high Ab titers against the viral surface proteins. In this study, we report the development of a 
recombinant form of the fourth domain of the bacterial toxin intermedilysin (the recombinant 
domain 4 of intermedilysin [rILYd4]), a 114 aa protein that inhibits human CD59 function with 
high affinity and specificity. In the presence of rILYd4, HIV-1 virions derived from either cell 
lines or peripheral blood mononuclear cells of HIV-1–infected patients became highly sensitive to 
complement-mediated lysis activated by either anti–HIV-1 gp120 Abs or by viral infection-
induced Abs present in the plasma of HIV-1–infected individuals. We also demonstrated that 
rILYd4 together with serum or plasma from HIV-1–infected patients as a source of anti–HIV-1 
Abs and complement did not mediate complement-mediated lysis of either erythrocytes or 
peripheral blood mononuclear cells. These results indicate that rILYd4 may represent a novel 
therapeutic agent against HIV-1/AIDS
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The complement system, a main effector of innate and acquired immunity, has the capacity 
to lyse and thereby inactivate pathogenic microorganisms, including enveloped viruses in 
the circulation of infected hosts. Complement-mediated lysis of pathogenic microorganisms 
including bacteria, viruses, yeasts and of cells infected by these pathogens is mediated by 
formation of a transmembrane pore, the membrane attack complex (MAC), which is formed 
by C9 polymerization triggered by activation of the complement cascades. Mammalian cells 
are protected against the devastating effect of complement activation and MAC formation 
by an array of complement regulators, including several membrane proteins such as CD55 
and CD59. CD59 is a GPI-linked complement regulatory protein, which specifically inhibits 
MAC formation and is universally expressed on the surface of mammalian cells (1, 2). It is 
well established that many pathogenic enveloped viruses, including HIV-1, CMV, herpes 
virus, Ebola virus, and influenza virus, escape complement-mediated virolysis by 
incorporating host cell complement-regulatory proteins into their own viral envelope (3–9). 
The presence of complement regulators such as CD59 on the external surface of the viral 
envelope confers resistance to Ab-dependent, complement-mediated lysis. This resistance to 
the lysis provides a likely explanation for the evidence that certain human pathogenic 
viruses are not neutralized by complement in human fluids even when they induce a strong 
Ab response. In the specific case of HIV-1, sera from patients with HIV-1 infection contain 
anti–HIV-1 envelope Abs, but these Abs fail to induce complement-mediated virolysis of 
HIV-1 virions and cytolysis of the virus-infected cells (3, 10, 11). This protection against 
complement-mediated lysis is conferred by the presence of CD59 in either the HIV-1 
envelope or the membrane of the infected cells (10). Deficiency or inhibition of CD59 in the 
surface of either the viral envelope or the infected cell membrane sensitizes them to the lytic 
effect of complement (3, 10, 12).
HIV-1 infection leading to AIDS is still a major public health challenge (13). Current 
treatment (highly active antiretroviral therapy [HAART]) can successfully control plasma 
levels of HIV-1 RNA below the limits of detection, but cannot eliminate infected cells and 
trace levels of free virions. If HAART is discontinued because of serious adverse effects or 
becomes ineffective because of development of drug resistance, HIV-1 contained in stable 
reservoirs rapidly rebounds and disease progression resumes (14). Further complicating 
problem of HIV-1 treatment and prevention is the fact that several anti–HIV-1 vaccine 
candidates have failed to show significant clinical efficacy, although they induced vigorous 
Ab responses (14). For these reasons, a therapeutic inhibitor of CD59 that would sensitize 
HIV-1 virions or HIV-infected cells to the lytic effect of complement has been actively 
sought by us and others (11).
In this study, we report the development of rILYd4, a high-affinity specific inhibitor of 
human CD59 (hCD59). rILYd4 is the recombinant form of the 114 aa domain 4 (D4) of 
intermedilysin (ILY), a cell lytic toxin secreted by Streptococcus intermedius. ILY is a pore-
forming toxin that exclusively lyses human cells, because it binds with high affinity and 
specificity to hCD59 but not to CD59 from other species (15, 16). Binding of ILY to hCD59 
occurs through D4, whereas the three other domains (domains 1, 2, and 3) of ILY form the 
lytic transmembrane pore (15). Because D4 of ILY binds to a region of hCD59 to 
encompass its active site (aa 42–58) (15, 17), we reasoned that rILYd4 would inhibit hCD59 
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function (2) and thereby enhance Ab-dependent complement-mediated virolysis of HIV-1. 
Our results show that rILYd4 potently enhances complement-mediated HIV-1 virolysis 
activated by anti–HIV-1-specific Abs with no or minimal bystander effects. We conclude 
that rILYd4 has strong potential as an anti–HIV-1 therapeutic agent, a notion that warrants 
further testing in animal studies and in human clinical trials.
Materials and Methods
Preparation of rILY
For the generation of a truncated rILYd4 fragment, sequences encoding the fragments were 
cloned into an expression vector pTrcHis A with a HisX6 tag. The 114 aa rILYd4 fragment 
contains only D4 of ILY: 
GALTLNHDGAFVARFYVYWEELGHDADGYETIRSRSWSGNGYNRGAHYSTTLRFKGNVR
NIRVKVLGATGLAWEPWRLIYSKNDLPLVPQRNISTWGTTLHPQFEDKVVKDNTD. His-
tagged rILYd4 was expressed in Escherichia coli and purified with the His•Bind purification 
kit (Novagen, San Diego, CA) as described previously (15).
FACS analysis
Erythrocytes from human and hCD59RBC transgenic mouse expressing hCD59 only on the 
mouse erythrocytes published previously (16) were preincubated with rILYd4 (1 µg/ml) or 
PBS for 10 min at room temperature, incubated with mouse anti-hCD59 monoclonal Ab (0.2 
µg/ml; BRIC 229; IBGRL Office, Bristol, U.K.) at room temperature for 30 min, washed, 
and incubated with a FITC-conjugated corresponding secondary Ab. The cells were washed 
with PBS three times before analyzing the fluorescence intensity using a FACScan (Becton 
Dickinson, Franklin Lakes, NJ).
Hemolytic assay
Human or mouse blood was obtained by venipuncture into a syringe containing sodium 
citrate (105 mM) as an anticoagulant (blood:buffer = 9:1 v/v). The erythrocytes were 
washed four times by PBS, stored in Alsever’s solution at 4°C, and used for hemolytic 
assays, as described previously (16). The amount of hemoglobin released from lysed 
erythrocytes was determined by the absorbance of the supernatant at 414 nm, and the 
percent lysis was calculated as follows: [(experimental OD414 − blank OD414)/(total lysis 
OD414 − blank OD414)]×100. The total lysis sample was obtained by adding pure water to 
the erythrocyte pellet.
Complement-mediated lysis on human erythrocytes
The sensitivity of human erythrocytes to human complement-mediated lysis in the presence 
or absence of rILYd4 was assessed by two different methods: cobra venom factor (5 mg/L) 
lysis assay and anti-human erythrocyte Ab-sensitized erythrocyte method, as described 
previously (16). As the source of complement, we used human serum (HS; 50% v/v diluted 
in GVB++ [CompTech, Tyler, Texas]) controlled by heat-inactivated HS (50%, v/v diluted 
in GVB++). In both cases, hemoglobin in the supernatant of lysed erythrocytes was 
measured by the absorbance at 414 nm, and percent lysis was calculated as follows: % lysis 
= (test OD414 − blank OD414)/(total lysis OD414 − blank OD414)×100.
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Complement-mediated cytolysis on human nuclear cells
Complement-mediated cytolysis of human nuclear cells was assessed by the Alamar blue 
assay (Serotec, Raleigh, NC) as described previously (18). Briefly, 5 × 104 human non-
Hodgkin lymphoma RL cells purchased from the American Type Culture Collection 
(Manassas, VA) were suspended in 100 µl RPMI 1640 medium supplemented with 10% 
heat-inactivated FBS and plated in 96-well plates. After an additional 100 µl of medium 
containing different concentration of rILYd4, rituximab (2 µg/ml), and 10% HS as the 
source of complement was added to the wells, the cells were incubated for 4 h at 37°C. 
Next, 70 µl culture medium plus 30 µl Alamar blue solution (Serotec) was added to the wells 
and incubated at 37°C overnight. Cell lysis was assessed by reading the plates in an F-2000 
fluorescence spectrophotometer (Hitachi, Tokyo, Japan; excitation, 560 nm; emission, 590 
nm). Percent cell lysis in each well was calculated as: (reading from the well without any 
treatment − reading from testing well)/(reading from the well without any treatment)×100. 
All pooled HS used as a source of complement in this study was purchased from 
Complement Technology (Tyler, TX).
Preparation of HIV-1 from HIV-1 chronically infected or permissive human cell lines
HIV-1 chronically infected U1 monocytic (hCD59-negative) and OM10 T-lymphocytic 
(hCD59-positive) human cell lines obtained from the National Institutes of Health AIDS 
Research and Reference Reagent Program (Germantown, MD) were used for preparation of 
HIV-1 virions. Cells were cultured in RPMI 1640 medium complemented with 10% heat-
inactivated FCS (Hyclone, Logan, UT), 2 mM glutamine, 100 U/ml penicillin, and 100 
µg/ml streptomycin. Cell viability was assessed by the trypan blue dye exclusion assay. All 
media and reagents used were endotoxin-free, as demonstrated by the limulus amebocyte 
lysate assay, and all cell lines were negative for Mycoplasma contamination, as documented 
using the Gen-Probe Mycoplasma T. C. Rapid Detection System (Gen-Probe, San Diego, 
CA). To induce viral replication, infected cells (1 × 106 cells/ml) were stimulated with TNF-
α (2 ng/ml) plus PMA (2 ng/ml). After 24 h of incubation at 37°C in 5% CO2, supernatants 
containing the virus were harvested and used as a source of HIV-1 virions. HIV-1 titers in 
cell culture supernatants were quantified by HIV-1 p24 ELISA Ag assay (PerkinElmer, 
Waltham, MA, or XpressBio, Thurmont, MD) as described below. All ELISA 
determinations were performed in duplicate. Human monocytic THP-1 and human T-
lymphocytic H9 (HTB 176) cell lines were obtained from the American Type Culture 
Collection and used to propagate the HIV-1 virus. Cells were grown in RPMI 1640 medium, 
supplemented with 10% FCS and antibiotics, and infected with HIV-1. Ten days after 
infection, cells were washed three times with culture medium and resuspended in culture 
medium for an additional 24 h. The fresh supernatants were harvested and used as inoculates 
of HIV-1 virions. HIV-1 titers in cell culture supernatants were also quantified by HIV-1 
p24 ELISA Ag assay (PerkinElmer or XpressBio). The lower limit of sensitivity of the assay 
for HIV-1 p24 was 26 pg/ml.
Preparation of six primary isolates of HIV-1 from HIV-1-infected patients
HIV-1 primary isolates were generated by coculture of PBMCs from HIV-1–infected and 
healthy donors, following methods described previously (19). PBMCs were prepared from 
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heparinized peripheral blood donated by six HIV-1–seropositive patients naive for 
antiretroviral therapy (patients 1–6 in Table I) and by HIV-1–seronegative donors. PBMCs 
from seronegative and seropositive individuals were stimulated separately for 2 d with PHA 
(5 µg/ml) and cocultured at a 1:3 ratio in the presence of IL-2 (10 ng/ml) in complete RPMI 
1640 medium (200 µl per well) in 96-well round-bottom plates. After 7 d of coculture, 
supernatants were harvested, aliquoted, and stored at −80°C as HIV-1 primary isolate stocks 
for virolysis assay.
Anti-gp120/gp160 Ab activated complement-mediated virolysis
HIV-1 virions (20 µl containing 5 ng HIV-1 p24/ml) were preincubated for 30 min at 37°C 
with or without rILYd4 (20 µg/ml) before exposure to anti–HIV-1-specific Abs (anti–HIV-1 
gp120 monoclonal Ab, IgG1B12, National Institutes of Health Reagent Program or gp120/
gp160 polyclonal Abs; Abcam, Cambridge, MA) and to the pooled HS as a source of 
complement (1:10 dilution in GVB++ buffer). Heat-inactivated HS was used as a negative 
control. Virolysis of HIV-1 was quantified using HIV-1 ELISA Ag assay (PerkinElmer). 
The ELISA procedure was the same as the manufacturer’s description, except for the use of 
the lysis buffer. As a consequence, we measured only the p24 released from the lysed viral 
particles triggered by the Ab-dependent complement-mediated virolysis. The p24 in the core 
of the intact HIV-1 virions was not detected; therefore, p24 release served a parameter of 
virolysis. HIV-1 virions were treated with Triton X-100 for determination of total virolysis. 
The percentage of virolysis was calculated as follows: (p24 released in the presence of 
complement-competent serum − p24 released in the presence of heat inactivated serum) / 
(p24 released from Triton X-100 treated virions − p24 released by medium only) × 100%. 
Means ± SD of three experiments were compared using the paired two-tailed Student t test.
Complement-mediated virolysis activated by anti–HIV-1 Abs in plasmas of HIV-1-infected 
patients
Viral preparations (20 µl; 5 ng HIV-1 p24/ml) derived from the chronically-infected cell line 
OM10 or from primary HIV-1 isolates were preincubated for 30 min at 37°C with either 
rILYd4 (20 µg/ml) or neutralizing anti-hCD59 monoclonal Ab (30 µg/ml; BRIC229). After 
preincubation, heat-inactivated plasma from either HIV-1–infected or healthy individuals 
(1:5 at final dilution) were individually added as a source of endogenous Abs, followed by 
the exposure to either complement-competent or heat-inactivated HS diluted in GVB++ 
buffer. Triton X-100 was used for determining the total virolysis. Experiments were 
conducted in duplicates and the paired two-tailed Student’s t test was used to compare the 
means ± SD.
Infectivity assay
Five microliters of reaction mixture from each condition in the virolysis experiment 
described above (patients 1–4 in Fig. 3A, 3B) were added to fresh H9 cells (0.2 × 106 cells 
per well in 200 µl complete RPMI 1640 medium), and cultured for 7–10 d. The infectivity 
was then assessed by measuring HIV-1 p24 in the culture supernatant using HIV-1 p24 
ELISA Antigen Assay (PerkinElmer). The lysis buffer included in the ELISA kit was used 
to lyse the viral particles for measuring HIV-1 core protein p24.
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Plasma collection from HIV-1–infected patients
Plasma specimens were obtained from the repository at the Hawaii Center for AIDS, 
University of Hawaii. All samples were from patients who signed informed consent forms in 
accordance with the guidelines for conduction of clinical research by the University of 
Hawaii Institutional Review Board. Plasma HIV-1 levels (Amplicor HIV-1 Monitor Ultra 
Sensitive Test, Roche Diagnostics, Basel, Switzerland) and CD4 cell counts were measured 
in a certified clinical laboratory, as previously reported (20).
Measurement of HIV-1 p24 in plasma samples from HIV-1–infected patients
Plasma specimens were tested for HIV-1 p24 Ag using the Perkin Elmer HIV-1 ELISA kit 
as described above. Each plasma sample was treated with the lysis buffer included in the 
ELISA kit to lyse the viral particles for releasing HIV-1 core protein p24, which was then 
measured.
Measurement of anti–HIV-1 envelope Abs from HIV-1–infected patients
Anti–HIV-1 envelope Ab was measured using an ELISA Kit for Antibody to Human 
Immunodeficiency Virus 1&2 (BioChain, Hayward, CA) according to the manufacturer’s 
protocol. The microplates included in this kit were coated with the rHIV Ags (gp120, gp36, 
and gp47), which specifically capture anti–HIV envelope Abs. Test results for HIV-2 
specific Ab, as measured by the FDA-licensed HIV-2 enzyme immunoassay, were negative 
in all subjects. Therefore, Abs measured by this ELISA kit were specifically against HIV-1 
envelope.
Assessment of the nonspecific cytolytic effect of rILYd4 on erythrocytes and PBMCs from 
HIV-1–infected patients
Fresh whole blood from HIV-1–infected patients (patients 14 and 17 in Table I) were 
collected into two tubes, one containing no anticoagulation reagent for serum isolation and 
one containing potassium EDTA as an anticoagulant for erythrocyte preparation. The tube 
without anticoagulation was kept at room temperature for 30 min and subjected to 
centrifugation at 10,000 rpm at 4°C for 15 min to separate serum from erythrocytes. The 
serum was aliquoted and stored at −80°C until used as a source of complement. Some serum 
aliquots were heated at 56°C for 30 min to inactivate complement. Erythrocytes and PBMC 
from the same HIV-1-infected patients were prepared as described above and their 
sensitivity to complement-mediated lysis in the presence of rILYd4 was assessed as follows. 
Erythrocytes were washed with PBS, suspended in GVB++ (hematocrit: 2%), treated with 
rILYd4 (20 µg/ml) at 37°C for 15 min, and then incubated with or without rabbit anti-human 
erythrocyte polyclonal Abs at 37°C for 30 min. Both nonsensitized and sensitized 
erythrocytes were exposed to 50% serum or plasma (as a source of complement) from the 
same HIV-1–infected patient. The effect of rILYd4 on PBMCs from the same HIV-1–
infected patient was also assessed as follows. PBMCs were prepared as described above, 
pretreated with rILYd4 (20 µg/ml) at 37°C for 15 min, suspended in GVB++, and exposed to 
the same patient’s serum or plasma (50%) as a source of complement. PBMC lysis was 
assessed by the release of lactate dehydrogenase measured with the CytoTox-ONE kit 
according to the manufacturers’ instructions (Promega, Madison, WI) (21). The fluorescent 
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signal was recorded at 560/590 nm using Fluostar Optima (BMG Labtech, Cary, NC). The 
background fluorescence of the PBS buffer was subtracted. Total lysis of PBMCs was 
induced with Triton X-100. Percent lysis was calculated as: (experimental fluorescent signal 
− blank fluorescent signal)/(total lysis fluorescent signal)×100.
Results
Generation of human CD59 specific inhibitor rILYd4
rILYd4 (MW, 18.6 kDa) was expressed in E. coli. (Fig. 1A) and purified as described in 
Materials and Methods. FACS analysis of both human and mouse erythrocytes that 
transgenically express hCD59 (16) demonstrated that rILYd4 blocked anti-hCD59 
monoclonal Ab binding to membrane hCD59 (Fig. 1B). At the functional level, rILYd4 
induced a significant and dose-dependent inhibition of human erythrocytes lysis mediated by 
the intact ILY (1.2 nM; Fig. 1C) and a significant increase of complement-mediated lysis of 
human erythrocytes triggered by either the alternative (Fig. 1D) or the classical activation 
pathways (Fig. 1E). No lysis was observed when human or hCD59 transgenic mouse 
erythrocytes were exposed to rILYd4 alone. Together, these experiments demonstrate that 
rILYd4 binds and inhibits the function of hCD59. These results confirm and extend our 
previous communication (22) and are comparable to those recently published by Hughes et 
al. (23).
rILYd4 sensitizes the HIV-1 virions derived from CD59-positive cell lines to complement-
mediated virolysis activated by anti–HIV-1 envelope Abs
As mentioned above, hCD59 protects HIV-1 from complement-mediated virolysis (3, 24). 
To test whether inhibition of hCD59 by rILYd4 sensitizes HIV-1 to complement-mediated 
virolysis, we derived HIV-1 particles from two different HIV-1–infected host human 
monocytic cell lines: THP-1 expresses and U1 is devoid of hCD59 in the cell membranes, as 
documented by FACS analysis with an anti-hCD59 specific Ab (Fig. 2A). Virolysis was 
quantitated by an ELISA that measured the release of HIV-1 core protein p24 from the lysed 
viral particles. HIV-1 virions derived from hCD59-negative U1 cells were highly sensitive 
to virolysis induced by anti–HIV-1 gp120 monoclonal Ab plus HS as a source of 
complement (Fig. 2B). In contrast, HIV-1 virions derived from hCD59-positive THP-1 cells 
were resistant to complement-mediated virolysis (Fig. 2B). Remarkably, preincubation of 
the HIV-1 virions derived from the infected THP-1 cells with rILYd4 rendered the virus 
sensitive to complement-mediated lysis. This virolysis enhancement did not occur in HIV-1 
virions derived from hCD59-negative U1 cells (Fig. 2C). In the presence of 20 µg/ml 
rILYd4, THP-1 cell-derived virions were almost as sensitive to complement-mediated lysis 
as the virions derived from CD59 negative U1 cells (Fig. 2C). Similar dose-dependent 
results were obtained with 1) HIV-1 virions derived from two additional human T-
lymphocytic cell lines (OM10 and H9), which express a high density of hCD59 on their cell 
membranes (Fig. 2D), and 2) with a different anti–HIV-1 Ab (anti-gp120/160 polyclonal 
Abs; Fig. 2E). Blocking hCD59 function with a neutralizing anti-hCD59 Ab increased 
complement-mediated virolysis, albeit with less potency than with rILYd4 (Fig. 2F). In all 
experiments depicted in Fig. 2B, 2C, 2E, and 2F, virolysis in the presence of HS is 
complement-mediated because it is totally abrogated by preincubation of serum at 56°C for 
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1 h. These results demonstrate that inhibition of hCD59 function by rILYd4 sensitizes 
HIV-1 virions to complement-mediated virolysis.
Abs in the plasma from the HIV-1–infected subjects exhibit their anti–HIV-1 activity in the 
presence of rILYd4
The presence of anti–HIV-1 envelope Abs in the blood of HIV-1–infected subjects fostered 
the notion that a hCD59 inhibitor would not protect and thereby sensitize circulating HIV-1 
virions to complement-mediated virolysis. We tested this predication ex vivo by exposing 
HIV-1 virions derived from a hCD59 positive cell line to heat-inactivated plasma samples 
from either HIV-1–infected (HIV-1plasma) or control plasmas from HIV-1 seronegative 
donors (Controlplasma), followed by incubation with a pool of normal HS as a source of 
complement. Table I shows that the plasma levels of Abs against HIV-1 envelope measured 
by ELISA. Although the Ab titer varied among HIV-1 patients, every plasma sample from 
this cohort contained anti–HIV-1 envelope Abs. Preincubation with rILYd4 dramatically 
increased complement-mediated virolysis of CD59-positive virions exposed to HIV-1plasma, 
but not to the Controlplasma (Fig. 3A–C). This effect of rILYd4 was comparable with, albeit 
much stronger than, the effect mediated by the anti-hCD59 monoclonal Ab BRIC229 (Fig. 
3B).
To understand the functional consequence of complement-mediated virolysis we used an 
HIV-1 infectivity assay. HIV-1–permissive H9 cells were exposed for 10 d to each 
conditioned medium from the virolysis experiments depicted in Fig. 3A and 3B (samples 1–
4). The culture supernatants were then collected to determine HIV-1 infection intensity by 
measuring HIV-1 p24 (ELISA). The higher the level of p24 in the culture supernatant, the 
higher the number of infectious viral particles that remained in the conditioned medium of 
the virolysis experiments. Fig. 3D shows that p24 was undetectable in the supernatant from 
H9 cells exposed to conditioned medium from Triton X-100 treatment (total lysis), 
indicating that potentially infective particles were totally lysed and no infectious viral 
particles remained. The supernatants from cells exposed for 10 d to control conditioned 
medium (i.e., conditioned by the virions not treated with rILYd4 before exposure to 
endogenous anti–HIV-1 Ab and complement) had high titers of p24, indicating that the viral 
particles were not lysed and their infectivity was preserved. In contrast, supernatants from 
cells exposed for 10 d to conditioned medium from rILYd4 pretreated virions (treated with 
rILYd4 before exposure to endogenous anti–HIV-1 Ab and complement) showed low levels 
of p24, an indication that rILYd4 allowed the anti–HIV-1 Abs present in the plasmas of 
HIV-1–infected patients to regain their activity in triggering complement-mediated virolysis 
and thereby reduce the infective potential of HIV-1 virions.
rILYd4 sensitizes primary HIV-1 isolates to complement-mediated virolysis activated by 
anti–HIV-1 Abs present in the plasmas of HIV-1–infected patients
Results obtained from primary HIV-1 isolates are considered more representatives of the 
physiologic conditions of HIV-1–infected patients than those obtained from cultured cell 
lines. In the specific case of hCD59, primary HIV-1 isolates derived from PBMC of HIV-1–
infected patients are likely to carry a load of membrane-derived human CD59, which 
confers resistance to the Ab-dependent complement-mediated virolysis. For these reasons, 
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we generated primary HIV-1 isolates from six HIV-1–seropositive individuals who were 
naive for antiretroviral therapy, and we tested whether rILYd4 sensitizes these virions to 
complement-mediated virolysis. In the same experiment, we assessed the relative potency of 
endogenous anti–HIV-1 Abs developed by HIV-1–infected patients to promote complement-
mediated virolysis of PBMC-derived HIV-1 primary isolates in the presence and absence of 
rILYd4. To this end, we pretreated the primary HIV-1 isolates with or without rILYd4 and 
exposed them to heat-inactivated HIV-1plasma (patients 1 to 5 in Table I), followed by 
incubation with pooled normal HS as a source of complement. The results showed that 
rILYd4 sensitized each of the six primary HIV-1 isolates to complement-mediated virolysis 
activated by HIV-1plasma (Fig. 4). In the presence of rILYd4, each of the five different 
HIV-1plasma samples tested significantly increased complement-mediated lysis of each of 
the six primary HIV-1 isolates (Fig. 5). These effects of rILYd4 were comparable with, 
albeit much stronger than, those mediated by the anti-hCD59 monoclonal Ab BRIC229 
(Figs. 4 and 5). These results confirm that rILYd4 sensitizes HIV-1 to complement-mediated 
virolysis not only under experimental conditions using cell lines and commercially available 
Abs, but also of primary HIV-1 isolates sensitized by the endogenous anti–HIV-1 Abs 
naturally present in the blood of HIV individuals. These results also indicate that inhibition 
of hCD59 with rILYd4 unprotects HIV-1, unleashing the ability of complement to lyse the 
virions sensitized by anti–HIV-1 Abs present in the circulation of patients with HIV-1.
rILYd4 does not mediate cytolytic effect on erythrocytes and PBMC in the blood from 
HIV-1–infected patients
Patients infected with HIV-1 are well known to mount a vigorous and sustained Ab response 
to the virus (25–30). We consistently detected anti–HIV-1 envelope Abs in all 16 plasma 
samples from HIV-1–infected patients (Table I). When hCD59 activity is inhibited by 
rILYd4, these Abs could conceivably trigger unwanted complement-mediated effects, such 
as hemolysis. To address this issue, we investigated the potential lytic effect of rILYd4 on 
erythrocytes and PBMC from the HIV-1–infected patients with high levels of plasma HIV-1 
RNA (patients 14 and 17 in Table I). We found that incubation of either erythrocytes or 
PBMC from HIV-1–seropositive individuals with 50% of their own serum (patient 17) or 
plasma (patient 14) in the presence of rILYd4 at the concentration that completely blocked 
hCD59 function did not result in any lytic effect of either cell type (Fig. 6A, 6B). This 
experiment indicates that rILYd4 does not induce complement-mediated lysis of cells not 
infected by HIV-1, such as erythrocytes. Although the infected CD4+ T cells in PBMC are 
susceptible to HIV-1 infection and might be lysed in the presence of rILYd4, they represent 
a small proportion of the overall PBMC population (0.001%–10%) (31), and their potential 
complement-mediated lysis in the presence of anti–HIV-1 Abs and rILYd4 is probably 
undetectable with the methods used for these experiments. These results suggest that 
bystander lytic effects induced by rILYd4 in the circulation of HIV-1 infected individuals 
are unlikely.
Discussion
In this study, we report the development of rILYd4, a potent and specific inhibitor of 
hCD59. We show that rILYd4, in conjunction with anti–HIV-1 Abs, either exogenous like 
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the anti-gp120/160 polyclonal Abs or endogenous such as those in plasma from HIV-1–
infected patients, efficiently abrogates hCD59 function and renders complement-resistant 
laboratory strains of HIV-1 sensitive to Ab-dependent, complement-mediated lysis. We also 
show that, in the presence of rILYd4, anti–HIV-1 Abs in the circulation of HIV-1–infected 
individuals are capable of triggering complement-mediated virolysis of primary HIV-1 
isolates. Inhibition of hCD59 activity by rILYd4 in erythrocytes or PBMC from HIV-1–
infected individuals does not induce unwanted lytic effects.
The complement system, a key member of innate immunity, is a first-line defender against 
foreign pathogens such as HIV-1. However, HIV-1 in the circulation escapes complement-
mediated attack and remains highly infective, even though there is strong experimental 
evidence that both the virus itself and anti–HIV-1 Abs in the blood of HIV-1–infected 
individuals are capable of activating the complement cascades (32). Indeed, HIV-1 virions 
from infected individuals accumulate C3 on their surface, an indication of complement 
activation (33). Normally, component C3 activation generates C3a and C3b, which then 
trigger a cascade of activation events that eventually result in formation of the MAC, an 
end-product of all the three complement activation pathways (2, 34). The MAC forms a lytic 
pore in the lipid bilayer membrane that destroys membrane integrity, allows the free passage 
of solutes and water, and eventually kills pathogens including viruses and/or infected cells. 
In HIV-1 infection, however, activation of complement, as evidenced by accumulation of C3 
on the surface of the HIV-1 virions, fails to induce the HIV-1 lysis and enhances the viral 
infectivity by facilitating the interaction of the HIV-1 particles with complement-receptor–
positive cells, including B and dendritic cells (35). Incomplete activation of complement 
enabling HIV-1 to escape Ab-dependent, complement-mediated lysis is due in part to the 
presence of hCD59 in the viral envelope, which the virus recruits from the host cell in the 
budding process (3, 10, 11). In addition, binding of the fluid phase complement regulator 
factor H to HIV-1 confers onto the virus further protection from complement attack (36). In 
summary, the HIV-1 virus, like other pathogens such as Schistosoma mansoni (37), 
manipulates the delicate balance between complement activation and restriction in a manner 
that is favorable to the virus.
For these reasons, it has long been suggested that an inhibitor of hCD59 or an agent that 
would abrogate factor H binding to the HIV-1 envelope could have a beneficial therapeutic 
effect against HIV-1 infection and AIDS (11, 33). The experiments reported in this paper 
indicate that rILYd4, a high affinity inhibitor of hCD59, could represent such a sought after 
therapeutic tool. Whether rILYd4 also abrogates the protective effect of factor H binding to 
HIV-1 is not known at present. More importantly, our experimental results show that 
rILYd4 abrogates hCD59 function and fosters complement-mediated cytolysis in human 
nucleated cells such as lymphocytes, which are the natural reservoir of HIV-1 in infected 
individuals (Supplemental Fig. 1). It has been documented that patients with HIV-1 
infection also have diminished expression of the GPI-anchored cell surface proteins CD55 
and CD59 on the erythrocytes and granulocytes (38). Because the density of hCD59 on the 
surface of HIV-1–infected cells appears to be reduced, one would expect that primary 
virions would carry less hCD59. Different density of CD59 in the membrane of laboratory 
or primary HIV-1 virions could explain different sensitivities to induction of complement-
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mediated lysis by rILYd4 (Fig. 3). In patients, a lower density of hCD59 in infected than in 
noninfected cells would enhance the efficacy of rILYd4 in specifically eliminating HIV-1 
virions and HIV-1–infected cells. In summary, the results presented in this paper indicate 
that rILYd4 represents a preclinical candidate that deserves further investigation as a 
potential therapeutic agent against HIV-1 infection and AIDS.
However, in the discussion of a potential therapeutic use of rILYd4, it is important to 
highlight that abrogation of hCD59 function in humans has the potential of inducing 
complement-mediated side effects. A pertinent example of the potentially harmful effects of 
abrogating homologous restriction on the surface of “self” cells is illustrated by the human 
disease paroxysmal nocturnal hemoglobinuria (PNH), in which bone marrow–derived 
circulating cells are deficient in CD59 and other GPI-anchored proteins (39–43). Patients 
with PNH usually exhibit a mild hemolytic anemia, attributed to complement activation at 
its basal “tick over” rate, and develop paroxysmal hemolytic crisis when infections of other 
stressors trigger more massive complement activation (39, 40). Of note, patients with a 
variety of autoimmune disorders also have diminished expression of the GPI-anchored cell 
surface proteins CD55 and CD59 on erythrocytes and granulocytes (44). Whether 
administration of rILYd4 to humans with PNH or autoimmune disorders will trigger 
hemolysis and/or other unwanted complement-mediated phenomena is not known at present 
and raises a question that can be answered only by human studies. Our preliminary attempts 
to address the potential complement-mediated adverse effects of inhibiting hCD59 function 
ex vivo have shown that incubation of erythrocytes and PBMCs from normal or HIV-1–
infected individuals in 50% HS or human plasma (HP) in the presence of rILYd4 at a 
concentration that maximally inhibits hCD59 function did not result in any spontaneous 
cytolysis. This finding indicates that the basal activity of complement in plasma/serum (as 
assessed ex vivo) is not sufficient to lyse human erythorcytes and PBMCs in the presence of 
a rILYd4 concentration that dramatically increased lysis when complement was activated by 
either the classical or alternative pathways (Figs. 1D, 1E, 6).
Plasma from HIV-1–infected patients, but not from healthy individuals, contains anti–HIV-1 
Abs that promote complement-mediated virolysis of HIV-1 primary isolates in the presence 
of rILYd4 (Fig. 3). These endogenous anti–HIV-1 Abs developed by HIV-1–infected 
individuals in both the acute and chronic phases of infection activate complement through 
the classical pathway, as indicated by published reports that C1q-deficient serum as a source 
of complement fails to induce anti–HIV-1 Ab-mediated virolysis (45). Fig. 3B shows that 
plasmas from HIV-1–infected individuals segregate into two distinct populations: one with 
higher and one with lower capacity to induce complement-mediated virolysis in the presence 
of rILYd4. This finding may be attributed to the different Ab titers and/or different 
complement-activating capacity of the endogenous anti–HIV-1 Abs present in those 
plasmas. Additional specificity for complement activation on the viral surface would be 
provided by direct activation of complement triggered by gp41 and gp120, two complement-
activating proteins present in the HIV-1 envelope (46, 47). Direct complement activation by 
viral proteins explains the complement-mediated virolysis seen in the presence of rILYd4, 
but in the absence of sensitizing anti–HIV-1 Abs (Fig. 3C).
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An interesting advantage of rILYd4 over current anti–HIV-1 pharmacologic therapies 
derives from the fact that hCD59 present in the viral surface is not encoded in the viral 
genome, but rather a human cell protein recruited from the membrane of the host cell in the 
budding process. For this reason, it is less likely that the HIV-1 virus in infected individuals 
would acquire resistance to rILYd4 through a high rate of mutation and recombination of 
viral proteins, as it does to all currently available anti–HIV-1 drugs and vaccines (48–50).
In conclusion, it is tempting to postulate that administration of rILYd4 to HIV-1–infected 
individuals would allow anti–HIV-1 Abs to unleash their capacities to induce complement-
mediated virolysis of both free viral particles and infected cells with no or minimal effect on 
other bystander cells. Further investigation of the potential therapeutic applications of 
rILYd4 for HIV-1 treatment certainly deserves consideration toward preclinical 
development and eventually clinical trials.
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FIGURE 1. 
Generation of rILYd4 and characterization of its functional activity as an inhibitor of 
hCD59. A, SDS-PAGE separation and Coomassie Blue staining of rILYd4 after purification. 
B, Confirmation of rILYd4 binding to hCD59 by FACS analysis. Preincubation of rILYd4 
inhibits binding of anti-hCD59 Abs to mouse erythrocytes from hCD59RBC mice (14) (top 
panel) and to human erythrocytes (bottom panel). The red curve represents isotype-matched 
Ab + FITC secondary Abs staining (negative control). The black curve represents ± rILYd4 
(0 or 1 µg/ml) + anti-hCD59 Abs (0.2 µg/ml) + FITC secondary Abs. C, rILYd4 blocked the 
lysis of human erythrocytes induced by 1.2nM ILY, which mediates ~90% hemolysis in 
vitro.D and E, rILYd4 abrogates hCD59 function in complement-mediated hemolytic 
assays. HS = 50% HS; HIS = 50% heat-inactivated HS. D, Alternative pathway assay 
activated by 5 mg/l cobra venom factor. E, Classical pathway assay with human RBC 
sensitized with anti-human RBC Ab. Results in C, D, and E are mean ± SD from four 
independent experiments.
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FIGURE 2. 
Effects of rILYd4 on complement-mediated virolysis of HIV-1 virions. A, CD59 expression 
in human monocytes chronically infected with HIV-1. Cells were stained with anti-hCD59 
(black lines) or isotype-matched Ab (solid gray lines). B, Complement-mediated virolysis of 
HIV-1 derived from either CD59-positive (THP-1) or CD59-negative (U1) cell lines. Viral 
preparations derived from CD59-expressing THP-1 or from CD59-negative U1 cells were 
incubated with anti–HIV-1 gp120 monoclonal Ab plus serum as a source of complement 
(heat-inactivated serum is a negative control). C, Effect of rILYd4 on HIV-1 virolysis. 
HIV-1 virions derived from either THP-1 or U1 cells were preincubated with rILYd4 (20 
µg/ml) and treated with anti–HIV-1 gp120 monoclonal Ab plus serum as a source of 
complement (heat-inactivated serum is a negative control). Virolysis was analyzed by 
ELISA titration of released viral protein p24. D, CD59 expression on OM10 cells and H9 
cells. E and F, Dose-dependent effects of rILYd4 and anti-hCD59 monoclonal Ab BRIC229 
on HIV-1 virolysis activated by anti–HIV-1 gp120/gp160 polyclonal Abs. In each 
experiment, treatments with culture medium alone or with Triton X-100 were used as blank 
and 100% virolysis, respectively. Mean ± SD of three experiments performed in duplicate.
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FIGURE 3. 
Endogenous anti–HIV-1 Abs induce complement-mediated virolysis in the presence of 
rILYd4. HIV-1 CD59-positive virions preincubated with rILYd4 (20 µg/ml), medium only, 
or anti-hCD59 monoclonal Ab (BRIC 229) were treated with heat-inactivated plasma from 
16 HIV-1–positive individuals containing anti–HIV-1 envelope Abs (individual levels of 
these Abs from patients 1–16 shown in Table I) followed by exposure to 10% normal HS as 
a source of complement (heat-inactivated normal serum was used as a negative control). A, 
Plasma from HIV-1–infected individuals induces complement-mediated virolysis in the 
presence of rILYd4. B, Pooled virolysis data from all plasma samples from HIV-1–infected 
individuals. Horizontal bars represent mean of virolysis values. C, rILYd4 enhances 
complement-mediated virolysis activated by plasma from HIV-1–infected but not from 
noninfected individuals. D, HIV-1 infectivity assay. Titration of produced p24 in culture 
supernatants from cells exposed for 10 d to conditioned medium from virions pretreated 
with the following conditions: medium alone, anti-CD59 Ab (BRIC 229), rILYd4, and 
Triton X or originally exposed to heat-inactivated serum. The experiments were repeated 
twice for each test. The results are represented by mean ± SD.
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FIGURE 4. 
HIV-1 primary isolates become sensitive to complement-mediated virolysis in the presence 
of rILYd4. HIV-1 primary isolates derived from six HIV-1–infected patients. PBMCs 
preincubated with rILYd4 (20 µg/ml), medium only, or anti-hCD59 monoclonal Ab (BRIC 
229) were treated with heat-inactivated plasma from 5 HIV-1–positive individuals 
containing anti–HIV-1 envelope Abs (patients 1–5 shown in Table I) followed by exposure 
to 10% normal HS as a source of complement (heat-inactivated normal serum was used as a 
negative control). Each panel represents the sensitivity of HIV-1 virions derived from one 
patient to complement-mediated virolysis activated by the endogenous anti–HIV-1 Abs 
developed in five HIV-1–infected patients who were naive for antiretroviral therapy. 
Horizontal lines represent the mean. Statistical significance (p < 0.01 versus medium 
treatment group) is indicated by an asterisk.
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FIGURE 5. 
In the presence of rILYd4, the endogenous anti–HIV-1 Abs destruct the HIV-1 virions 
through complement-mediated virolysis. Another method to analyze the results shown in 
Fig. 4 documents that in the presence of rILYd4, the endogenous anti–HIV-1 Abs developed 
in six HIV-1–infected patients are capable of destroying HIV-1 virions through 
complement-mediated virolysis. Each panel represents the ability of the endogenous anti–
HIV-1 Abs developed in one patient to destroy the HIV-1–infected PBMC-derived virions. 
Horizontal lines represent the mean. Statistical significance (p < 0.01 versus medium 
treatment group) is indicated by an asterisk.
Hu et al. Page 20
J Immunol. Author manuscript; available in PMC 2014 December 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 6. 
Incubation of HIV-1–infected patient’s erythrocytes and PBMCs with 50% HIV-1–infected 
patient’s serum or plasma in the presence of rILYd4 did not result in a nonspecific lytic 
effect on the erythrocytes and PBMCs. A, The HS from and HIV-1–infected patient (patient 
17 in Table I) was used as a source of complement and anti–HIV-1 Abs to investigate the 
bystander effect of rILY4 on the erythrocytes. B, The HP from an HIV-1-infected patient 
(patient 14 in Table I) was used as a source of complement and anti–HIV-1 Abs to 
investigate the bystander effect of rILYd4 on the RBCs or PBMCs. The patient’s 
erythrocytes were sensitized by anti-human erythrocyte Abs and exposed to HP or heat-
inactivated HP. The results are the mean values ± SD from three experimental results. 
rILYd4, in the presence of rILYd4 (20 µg/ml), HIV-1–infected patients’ cells were exposed 
to 50% HS or HP and heat-inactivated HS or HP; Abs, HIV-1 infected patients’ erythrocytes 
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were sensitized by anti-human erythrocyte Abs and then exposed to 50% HS or HP as well 
as heat-inactivated HS or HP; rILYd4 + Abs, in the presence of rILYd4 (20ug/ml), HIV-1–
infected patients’ erythrocytes were sensitized by anti-human erythrocyte Abs and then 
exposed to 50% HS or HP and heat-inactivated HS or HP. *p < 0.01 versus heat-inactivated 
HS or HP treatment in rILYd4 + Abs.
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